(2010). Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database. Diabetes Care. http://doi.org/10.2337/dc09-2227.
(2013). A simple prediction rule for all-cause mortality in a cohort eligible for bariatric surgery. JAMA Surg. http://doi.org/10.1001/jamasurg.2013.3953.
(2016). Comparative effectiveness of incretin-based therapies and the risk of death and cardiovascular events in 38,233 metformin monotherapy users. Medicine (Baltimore). http://doi.org/10.1097/md.0000000000003995.
(2017). Association of insulin dosage with mortality or major adverse cardiovascular events: a retrospective cohort study. Lancet Diabetes Endocrinol. http://doi.org/10.1016/s2213-8587(16)30316-3.
(2018). The risk of fragility fractures in new users of dipeptidyl peptidase-4 inhibitors compared to sulfonylureas and other anti-diabetic drugs: A cohort study. Diabetes Res Clin Pract. http://doi.org/10.1016/j.diabres.2017.12.008.
(2018). Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK Clinical Practice Research Datalink. BMJ Open. http://doi.org/10.1136/bmjopen-2018-023830.
(2018). Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas and Other Glucose-lowering Therapies for Three Acute Outcomes. Sci Rep. http://doi.org/10.1038/s41598-018-33483-y.